According to ClinicalTrials.gov, the BIIB094 study record was updated on August 26, 2019. That is when the recruitment status of the study was changed from Not Yet Recruiting to Recruiting.
The estimated enrollment (number of patients able to participate in this phase of the trial) is 62 and the study is scheduled to start on September 21, 2019. (Which suggests that anyone who wants to participate in this trial should probably hurry – while there are still spots remaining.)
Here is some more information from the official BIIB094 clinical trial page and also a link to the study page where you can find all the important details, contact information, and so on.
The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson’s Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094. The study is open for PD patients with verified presence or absence of mutations in the leucine-rich repeated kinase 2 (LRRK2) gene, but also for patients without any verified PD-related genetic mutation.
LOCATIONS (Where is the study taking place?)
The study is currently recruiting in 3 locations: Michigan, Tennessee, and Washington.